Allergan has reached a settlement in a class action lawsuit related to an Alzheimer’s med. According to the plaintiffs, the company made an illegal agreement with Mylan to delay the introduction of a generic to its Alzheimer’s treatment, Nameda.
Nameda, which was first approved in 2003, was originally made by Forest. In 2014, Forest dropped the twice-daily medication and then released a new once-daily version of the drug in 2015, Allergan bought the company. The suit alleges that this “hard switch” maneuver forced patients onto the newer version and delayed access to a generic version.
The lawsuit was headed to trial this week. As part of the suit, Allergen admitted no wrong-doing.
Read the Reuters report.
